Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05GQL
|
|||
Former ID |
DIB005828
|
|||
Drug Name |
KNI-102
|
|||
Synonyms |
Kni-102; Kni 102; 139694-65-8; Rpi 312; CHEBI:80005; AHPBA 1a; Z-Asn-apns-pro-NH-t-but; RPI-312; Cbz-Asn-Apns-Pro-NH-tBu; AC1Q5L2D; BDBM4215; AC1L22E8; SCHEMBL2771668; Z-Asparaginyl-allophenylnorstatinyl-t-butylproline amide; CHEMBL3349847; DTXSID70161152; 1-(3-(N-alpha-Benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutyryl)-N-tert-butyl-L-prolinamide; C15654; benzyl N-[(2S)-4-amino-1-[[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamate
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Terminated | [1] | |
Company |
Japan Energy Corp
|
|||
Structure |
Download2D MOL |
|||
Formula |
C31H41N5O7
|
|||
Canonical SMILES |
CC(C)(C)NC(=O)C1CCCN1C(=O)C(C(CC2=CC=CC=C2)NC(=O)C(CC(=O)N)NC(=O)OCC3=CC=CC=C3)O
|
|||
InChI |
1S/C31H41N5O7/c1-31(2,3)35-28(40)24-15-10-16-36(24)29(41)26(38)22(17-20-11-6-4-7-12-20)33-27(39)23(18-25(32)37)34-30(42)43-19-21-13-8-5-9-14-21/h4-9,11-14,22-24,26,38H,10,15-19H2,1-3H3,(H2,32,37)(H,33,39)(H,34,42)(H,35,40)/t22-,23-,24-,26-/m0/s1
|
|||
InChIKey |
XCVUOCMQYKSJJR-IGRGDXOOSA-N
|
|||
CAS Number |
CAS 139694-65-8
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:80005
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Modulator | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002506) | |||
REF 2 | KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo). 1991 Nov;39(11):3088-90. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.